In a phase-I study using liposomal curcumin in metastatic tumor patients, they obtained steady plasma concentrations with a substantial but brief reduction in tumor markers, including CEA (Carcinoembryonic antigen), PSA (prostate-specific antigen), and CA 19–9 (cancer antigen). Here, CEACAM5 is linked to neoplasm.